Urticaria, commonly known as hives, creates intensely itchy welts on the skin that can suddenly appear and disappear without warning, affecting roughly one in five people at some point in their lives. Managing this condition involves understanding triggers, exploring both established and emerging treatment options, and working closely with healthcare providers to reduce the burden of symptoms and improve daily comfort.

Understanding Treatment Goals for Urticaria

The main aim when treating urticaria is to bring relief from the intense itching and visible welts that disrupt daily life. Treatment decisions vary depending on whether the condition is short-lived or long-lasting, the severity of symptoms, and how each person responds to different approaches.^[1] For many patients, the immediate focus is on calming the immune system’s overreaction and reducing the release of histamine—a chemical in the body that causes the skin to swell, turn red, and itch intensely.

When urticaria lasts less than six weeks, it’s classified as acute urticaria, while cases persisting beyond six weeks are termed chronic urticaria.^[2] Acute episodes often resolve on their own or with minimal intervention, but chronic forms may require ongoing management strategies. Treatment is rarely about curing the condition outright—especially when the cause remains unknown—but rather about controlling symptoms, preventing flare-ups, and helping patients regain control over their lives.

Both standard therapies approved by medical societies and newer investigational treatments being studied in clinical trials play a role in this process. Standard treatments have been used for years and are well understood, while clinical trials test promising new medications that might offer hope to patients who don’t respond well to existing options.^[3] Understanding what each approach offers helps patients and doctors make informed decisions together.

Standard Treatment Approaches

The cornerstone of treating urticaria—whether acute or chronic—is the use of medications called antihistamines. These drugs work by blocking histamine receptors on cells, preventing histamine from triggering the chain reaction that leads to swelling and itching.^[1] Second-generation antihistamines are typically recommended as the first line of treatment because they are less likely to cause drowsiness compared to older antihistamines.

Examples of second-generation antihistamines include cetirizine, loratadine, fexofenadine, desloratadine, and levocetirizine. These medications are usually taken once daily and are generally well tolerated.^[11] If standard doses don’t fully control symptoms, doctors may increase the dose—sometimes up to four times the normal amount—without significantly raising the risk of side effects.^[10] This dose escalation is often done gradually, allowing the healthcare team to find the lowest effective dose for each patient.

When second-generation antihistamines alone are not enough, older first-generation antihistamines such as diphenhydramine or hydroxyzine may be added, particularly at night, because they can help with sleep despite their sedating effects.^[11] However, their use during the day is limited due to drowsiness and other side effects like dry mouth and confusion, especially in older adults.

Another class of medications sometimes used alongside antihistamines is H2 blockers, which are typically prescribed for stomach acid issues but can also help with hives by blocking a different type of histamine receptor. Drugs like famotidine and ranitidine may provide modest additional benefit when combined with H1 antihistamines, though the evidence is not as strong.^[11]

Leukotriene receptor antagonists such as montelukast are sometimes added to the treatment plan, particularly for patients who have trouble tolerating nonsteroidal anti-inflammatory drugs or who experience cold-induced urticaria.^[10] These medications block another inflammatory pathway in the body and may help reduce the frequency and intensity of hives.

For severe flare-ups, a short course of oral corticosteroids such as prednisone may be prescribed for five to seven days.^[11] These powerful anti-inflammatory drugs can quickly calm widespread inflammation and provide relief, but they are not suitable for long-term use due to serious side effects like weight gain, high blood pressure, bone loss, and increased infection risk. Doctors typically reserve corticosteroids for short-term rescue therapy during particularly severe episodes.

In addition to medications, identifying and avoiding triggers is a key part of managing urticaria. Common triggers include certain foods (such as peanuts, shellfish, eggs, and milk), medications (especially antibiotics like penicillin), insect stings, physical stimuli (such as pressure, heat, cold, or sunlight), infections, and stress.^[1][4] Unfortunately, in many cases—particularly chronic urticaria—no clear trigger can be identified, and the condition is considered idiopathic, meaning its cause is unknown.

Therapy duration varies widely. Acute urticaria often resolves within days to weeks, while chronic urticaria may require treatment for months or even years. More than half of patients with chronic urticaria experience improvement or complete resolution within one year, though the condition can be unpredictable.^[6]

Treatment in Clinical Trials

For patients who do not respond adequately to standard antihistamine therapy, clinical trials offer access to newer treatments that target different mechanisms in the immune system. One of the most significant advances in recent years has been the approval of omalizumab, a monoclonal antibody that targets immunoglobulin E (IgE), a key player in allergic reactions.^[9]

Omalizumab is administered as a subcutaneous injection (under the skin) once a month, typically at a dose of 150 or 300 milligrams. It works by binding to IgE antibodies in the bloodstream, preventing them from attaching to mast cells and basophils—the cells that release histamine and other inflammatory chemicals.^[11] Clinical trials have shown that omalizumab is effective in approximately 80 percent of patients with chronic urticaria who have not responded to antihistamines, significantly reducing itching and the number of hives.^[11] It has a favorable safety profile, though rare cases of serious allergic reactions (anaphylaxis) have been reported, so the first doses are typically given in a clinical setting where immediate medical help is available.

Another biologic therapy approved for chronic spontaneous urticaria is dupilumab, which targets the interleukin-4 receptor alpha subunit.^[11] By blocking this receptor, dupilumab reduces signaling pathways involved in inflammation. It is given as a subcutaneous injection every two weeks and has shown promise in clinical trials for patients who do not respond to other treatments. Dupilumab is part of a broader class of medications targeting specific immune pathways, reflecting a growing understanding of the complex biology underlying chronic urticaria.

In 2025, the U.S. Food and Drug Administration approved remibrutinib, an oral medication that inhibits Bruton’s tyrosine kinase (BTK), an enzyme involved in mast cell activation.^[11] Remibrutinib offers an effective oral alternative to injectable biologics for patients with chronic spontaneous urticaria who do not respond adequately to antihistamines. Clinical studies have demonstrated that it reduces symptoms and has a favorable safety profile, making it an important addition to the treatment landscape.

For patients with chronic urticaria that remains difficult to control despite biologics and antihistamines, other immunosuppressive medications are sometimes tested in clinical trials. These include cyclosporine, which suppresses the immune system by affecting T-cells, and mycophenolate mofetil, methotrexate, colchicine, dapsone, and hydroxychloroquine, which have anti-inflammatory properties and may help in cases involving urticarial vasculitis, a related condition where hives are associated with inflammation of blood vessels.^[11]

Clinical trials testing these medications typically proceed through three phases. Phase I trials focus on safety, testing the drug in a small number of healthy volunteers or patients to assess how it is absorbed, metabolized, and whether it causes serious side effects. Phase II trials involve a larger group of patients and aim to determine whether the drug is effective at treating the condition and to identify the optimal dose. Phase III trials compare the new treatment against standard therapies or placebo in large groups of patients, providing robust evidence of effectiveness and safety before regulatory approval is sought.^[13]

Clinical trials for urticaria are conducted in many countries, including the United States, Europe, and other regions, and may accept patients based on specific eligibility criteria such as disease severity, prior treatment history, and overall health. Patients interested in participating in clinical trials should discuss this option with their healthcare provider, who can help identify appropriate studies and explain potential benefits and risks.

Most Common Treatment Methods

• Antihistamines
  • Second-generation antihistamines (cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine) are the first-line treatment, taken once daily and can be increased up to four times the standard dose if needed.
  • First-generation antihistamines (diphenhydramine, hydroxyzine) may be used at night due to their sedating effects, but are limited during the day because of drowsiness.
  • H2 blockers (famotidine, ranitidine) may be added to H1 antihistamines for additional symptom control.
• Leukotriene Receptor Antagonists
  • Montelukast is sometimes added to antihistamines, particularly for patients with cold urticaria or intolerance to nonsteroidal anti-inflammatory drugs.
• Corticosteroids
  • Short courses of oral prednisone (typically 5 to 7 days) are used for severe flare-ups to quickly reduce inflammation.
  • Long-term use is avoided due to serious side effects.
• Biologic Therapies
  • Omalizumab is a monoclonal antibody given as a monthly injection that targets IgE antibodies, effective in approximately 80 percent of patients with chronic urticaria who do not respond to antihistamines.
  • Dupilumab is another biologic therapy targeting the interleukin-4 receptor, given as an injection every two weeks.
• Tyrosine Kinase Inhibitors
  • Remibrutinib is an oral medication approved in 2025 that inhibits Bruton’s tyrosine kinase, offering an effective oral alternative to injectable biologics.
• Immunosuppressive Medications
  • Cyclosporine, mycophenolate mofetil, methotrexate, colchicine, dapsone, and hydroxychloroquine may be used in refractory cases or when urticarial vasculitis is present.
• Trigger Avoidance and Lifestyle Modifications
  • Identifying and avoiding triggers such as certain foods, medications, physical stimuli (heat, cold, pressure), stress, and infections is an important part of management.
  • Keeping a symptom diary can help identify patterns and potential triggers.

Self-Care and Lifestyle Adjustments

Beyond medications, self-care strategies play an important role in managing urticaria and reducing the frequency and severity of flare-ups. Many patients find that simple lifestyle adjustments can make a noticeable difference in their comfort and quality of life.

Managing stress is one of the most important self-care measures. Stress is a known trigger for urticaria and can worsen symptoms even when other triggers are controlled.^[16] Techniques such as yoga, walking, progressive muscle relaxation, breathing exercises, meditation, and therapy can help patients better manage stress and reduce the likelihood of flare-ups. While these practices do not provide instant relief, regular practice can lead to meaningful improvements over time.

Getting enough sleep is also crucial, as poor sleep can weaken the immune system and increase stress reactivity, both of which can contribute to urticaria flare-ups.^[17] Building better sleep habits, such as maintaining a consistent sleep schedule and creating a relaxing bedtime routine, can support overall health and symptom control.

Temperature extremes—both hot and cold—can trigger hives in susceptible individuals. Taking lukewarm showers instead of very hot or very cold ones, avoiding extreme outdoor temperatures, and being cautious with hot or cold foods and beverages can help prevent temperature-induced flare-ups.^[17] Some patients may benefit from gradual desensitization under medical supervision, where they slowly expose themselves to triggering temperatures over time.

Clothing choices matter as well. Tight or scratchy clothing can irritate the skin and trigger pressure-induced hives. Wearing loose, soft, cotton clothing instead of tight synthetic fabrics can reduce mechanical irritation.^[17] Similarly, avoiding excessive rubbing or scratching of the skin is important, as physical stimulation can worsen hives or cause new welts to appear.

Sun protection is essential for patients with solar urticaria, a form of the condition triggered by sunlight exposure. Using broad-spectrum sunscreen, wearing protective clothing, and seeking shade during peak sun hours can help prevent light-induced flare-ups.^[17]

Keeping the skin moisturized with fragrance-free lotions can provide soothing relief and help maintain the skin’s protective barrier. Cool compresses or oatmeal baths can also provide temporary relief from itching.^[19] Limiting showers and baths to 10 minutes and using mild, fragrance-free soaps can prevent further drying and irritation of the skin.

Diagnosis and Monitoring

Diagnosing urticaria is typically straightforward and based on clinical examination. A healthcare provider will examine the skin, ask about the pattern and duration of symptoms, and inquire about potential triggers.^[2] One characteristic feature of urticaria is that individual welts usually last less than 24 hours and disappear without leaving marks, though new welts may continue to appear.

For chronic urticaria, doctors may ask patients to keep a detailed diary tracking activities, foods, medications, environmental exposures, and the appearance and duration of hives. This information can help identify patterns and potential triggers.

Laboratory testing is generally not necessary for acute urticaria, but for chronic cases, a limited workup may be recommended to rule out underlying conditions. Common tests include a complete blood count with differential, measurement of erythrocyte sedimentation rate or C-reactive protein (markers of inflammation), thyroid function tests, urinalysis, and liver function tests.^[10] More extensive testing is only pursued if the history or physical examination suggests specific underlying diseases such as autoimmune disorders or infections.

In cases where urticarial vasculitis is suspected—characterized by hives that last longer than 24 hours, are painful rather than itchy, and may leave bruising or discoloration—a skin biopsy may be performed to look for inflammation of blood vessels.^[3] Additional tests such as complement levels and screening for autoimmune diseases may also be warranted in these cases.

Outlook and Long-Term Management

The prognosis for urticaria varies depending on whether it is acute or chronic. Acute urticaria typically resolves on its own within days to weeks, often without the need for long-term treatment. Most cases of acute urticaria are self-limited, and patients can return to normal activities once the episode passes.^[6]

Chronic urticaria is more unpredictable. While symptoms can persist for months or years, more than half of patients experience significant improvement or complete resolution within one year.^[6] However, some individuals may have symptoms that last for many years, requiring ongoing management and adjustments to their treatment plan.

Even when the underlying cause cannot be identified, effective symptom control is usually achievable with appropriate treatment. The key is working closely with a healthcare provider—often an allergist or dermatologist—to find the right combination of medications, lifestyle adjustments, and trigger avoidance strategies.

For patients whose urticaria does not respond to standard treatments, referral to a specialist and consideration of clinical trials or newer therapies such as biologics or immunosuppressants can offer new hope and improved quality of life.